Advaxis announces master clinical trial agreement
March 2014
by  |  Email the author


PRINCETON, N.J.—Biotechnology company Advaxis Inc. has announced an expansion of its collaboration with the GRU Cancer Center at Georgia Regents University by way of a master clinical trial agreement to conduct four Phase 1/2 clinical trials. The trials will study ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer, Advaxis’ two lead immunotherapies. The trials will evaluate ADXS-HPV in patients with surgically treatable cervical cancer prior to surgery, the optimal dose of ADXS-HPV and PD-1 antibody in patients with recurrent or refractory cervical cancer and high dose, repeating cycles of the drug in recurrent or refractory cervical cancer. The trials will also look at ADXS-cHER2 in women with Her2/neu over-expressing breast cancer with measurable disease who have progressed after prior standard therapy. Dr. Samir Khleif, director of GRU Cancer Center, will supervise the trials.

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.